65,437 trials
Chronic Obstructive Pulmonary Disease (COPD) · Asthma
Primary: Subjects With ≥1 Treatment-emergent Adverse Event — 2; 3; 2; 2 Participants
T Acute Lymphoblastic Leukemia · T Lymphoblastic Lymphoma
Primary: Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV) — 89.01; 90.53; 78.07; 86.46 percent probability
Smoking
Primary: Change From Baseline Plasma Concentration of Nicotine/Cotinine After Each ad Libitum Use Session. — 1.7621; 2.4113; 1.9446; 5.5571 (ng/mL)
Healthy · Lean
Primary: Changes in NT-proANP From Baseline to 8 Hours — -0.33 nmol/l
Healthy Subjects
Primary: Maximum Observed Plasma Concentration (Cmax) of Guaifenesin — 1770; 1810; 11.3; 11.3 ng/mL
PAD
Primary: Acute Technical Success — 33.6 Change in RDS (%)
Heart Failure
Primary: Percentage of Patients Free From Lead, Delivery System and Implant Related Complications. — 82.2 percentage of patients
Cardiovascular Diseases
Primary: Statin Prescribing Rate — 40; 116; 117 Participants
Dry Eye
Primary: Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score — -12.85 Scores on a scale — p=.001
Polycythemia Vera
Primary: Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) in Part A of the Study — 3; 3; 3; 3 Participants
Dementia With Lewy Bodies · Dementia
Primary: Timed up and go Cognitive — -6.49; -13.35 seconds
Unresectable Malignant Neoplasm · Melanoma · Metastatic Melanoma
Primary: Resectability Rate — 8; 2 Participants
Diabetes
Primary: Glycemic Control, Measured by Change in Adjusted Mean HbA1c (%) From Baseline to Immediate Post-intervention, 6 Months Post-intervention, and 12 Months…
Type 2 Diabetes
Primary: Mean Daily Blood Glucose Concentration Inpatient — 177.1; 154.1; 166.1 mg/dL
Ulcerative Colitis
Primary: Safety and Tolerability of SER-287 — 7; 5; 2; 8 Participants